Evaluation of 4-alkoxychalcones as a new class of antiglycating agents: a combined experimental and docking study

摘要

A series of 4-alkoxychalcones (1-12) has been evaluated for their in vitro antiglycation activity. Compound 2 (IC50 = 89.07 +/- 1.3 mu M), compound 3 (IC50 = 266.82 +/- 4.6 mu M), and compound 5 (IC50 = 285.79 +/- 1.9 mu M) showed an excellent antiglycation potential better than the standard (rutin, IC50 = 294.50 +/- 1.5 mu M). Additionally, all the compounds of this series were evaluated for their cytotoxicity against Artemia salina (brine shrimp) and one tumor cell line, namely human Prostate Cancer cell line (PC-3). All the compounds showed low toxicity against brine shrimp with LD50 values much lower than the standard etoposide. Similarly, a much lower toxicity was observed for all the compounds against PC-3 cell line compared to doxorubicin, a standard reference drug used for this study. The molecular docking studies were also carried out to support the experimental results. A good correlation was found between experimental and theoretical results. The compounds of this series are therefore excellent antiglycating agents with no or very little cytotoxicity and represent a new class of antiglycating agents that deserve to be focused on for further research and in vivo studies in the future.